A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy

المؤلفون المشاركون

Zeng, Si-yu
Lu, Hui-qin
Yan, Qiu-jiang
Zou, Jian

المصدر

PPAR Research

العدد

المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-8، 8ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2018-07-19

دولة النشر

مصر

عدد الصفحات

8

التخصصات الرئيسية

الأحياء

الملخص EN

The peroxisome proliferator-activated receptor-α (PPAR-α) agonist fenofibrate ameliorates cardiac hypertrophy; however, its mechanism of action has not been completely determined.

Our previous study indicated that a disintegrin and metalloproteinase-17 (ADAM17) is required for angiotensin II-induced cardiac hypertrophy.

This study aimed to determine whether ADAM17 is involved in the protective action of fenofibrate against cardiac hypertrophy.

Abdominal artery constriction- (AAC-) induced hypertensive rats were used to observe the effects of fenofibrate on cardiac hypertrophy and ADAM17 expression.

Primary cardiomyocytes were pretreated with fenofibrate (10 μM) for 1 hour before being stimulated with angiotensin II (100 nM) for another 24 hours.

Fenofibrate reduced the ratios of left ventricular weight to body weight (LVW/BW) and heart weight to body weight (HW/BW), left ventricular anterior wall thickness (LVAW), left ventricular posterior wall thickness (LVPW), and ADAM17 mRNA and protein levels in left ventricle in AAC-induced hypertensive rats.

Similarly, in vitro experiments showed that fenofibrate significantly attenuated angiotensin II-induced cardiac hypertrophy and diminished ADAM17 mRNA and protein levels in primary cardiomyocytes stimulated with angiotensin II.

In summary, a reduction in ADAM17 expression is associated with the protective action of PPAR-α agonists against pressure overload-induced cardiac hypertrophy.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Zeng, Si-yu& Lu, Hui-qin& Yan, Qiu-jiang& Zou, Jian. 2018. A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy. PPAR Research،Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1212527

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Zeng, Si-yu…[et al.]. A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy. PPAR Research No. 2018 (2018), pp.1-8.
https://search.emarefa.net/detail/BIM-1212527

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Zeng, Si-yu& Lu, Hui-qin& Yan, Qiu-jiang& Zou, Jian. A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy. PPAR Research. 2018. Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1212527

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1212527